Related references
Note: Only part of the references are listed.Global prediction of primary liver cancer incidences and mortality in 2040
Chenxi Li et al.
JOURNAL OF HEPATOLOGY (2023)
HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs
Sho Watanabe et al.
THORACIC CANCER (2021)
Benproperine, an ARPC2 inhibitor, suppresses cancer cell migration and tumor metastasis
Yae Jin Yoon et al.
BIOCHEMICAL PHARMACOLOGY (2019)
Drug repurposing: progress, challenges and recommendations
Sudeep Pushpakom et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
D. Westover et al.
ANNALS OF ONCOLOGY (2018)
Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies
Sun Min Lim et al.
CANCER TREATMENT REVIEWS (2018)
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients
Zhe Yang et al.
CLINICAL CANCER RESEARCH (2018)
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials
G. M. O'Kane et al.
CURRENT ONCOLOGY (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer
Pei-Chih Lee et al.
CANCER CELL (2018)
Systematic polypharmacology and drug repurposing via an integrated L1000-based Connectivity Map database mining
Tsang-Pai Liu et al.
ROYAL SOCIETY OPEN SCIENCE (2018)
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2017)
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
Collin M. Blakely et al.
NATURE GENETICS (2017)
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Tsukasa Shibue et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Aravind Subramanian et al.
CELL (2017)
KRIBB11 accelerates Mcl-1 degradation through an HSF1-independent, Mule-dependent pathway in A549 non-small cell lung cancer cells
Min-Jung Kang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating HSP90-EGFR association
Y-C Yang et al.
ONCOGENE (2016)
Heat Shock Factor 1 Is a Substrate for p38 Mitogen-Activated Protein Kinases
Sharadha Dayalan Naidu et al.
MOLECULAR AND CELLULAR BIOLOGY (2016)
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
Jacob J. Chabon et al.
NATURE COMMUNICATIONS (2016)
The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic
Katerina Politi et al.
CANCER CELL (2015)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih-Hsin Yang et al.
LANCET ONCOLOGY (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer
L. V. Sequist et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants
Thomas L. Prince et al.
PLOS ONE (2015)
MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation
Jin Kyung Rho et al.
CANCER RESEARCH (2014)
Tumour heterogeneity and the evolution of polyclonal drug resistance
Rebecca A. Burrell et al.
MOLECULAR ONCOLOGY (2014)
Acquired resistance to TKIs in solid tumours: learning from lung cancer
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition
Catherine Wilson et al.
ONCOTARGET (2014)
Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
Alexis B. Cortot et al.
EUROPEAN RESPIRATORY REVIEW (2014)
An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Lauren Averett Byers et al.
CLINICAL CANCER RESEARCH (2013)
Molecular Mechanism of 17-Allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL Receptor Tyrosine Kinase Degradation
Gnana Prakasam Krishnamoorthy et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Tight Coordination of Protein Translation and HSF1 Activation Supports the Anabolic Malignant State
Sandro Santagata et al.
SCIENCE (2013)
HSF1 Drives a Transcriptional Program Distinct from Heat Shock to Support Highly Malignant Human Cancers
Marc L. Mendillo et al.
CELL (2012)
Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis
Hitomi Koizumi et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Systematic Identification of the HSP90 Candidate Regulated Proteome
Zhixiang Wu et al.
MOLECULAR & CELLULAR PROTEOMICS (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Wild-type EGFR Is Stabilized by Direct Interaction with HSP90 in Cancer Cells and Tumors
Aarif Ahsan et al.
NEOPLASIA (2012)
KRIBB11 Inhibits HSP70 Synthesis through Inhibition of Heat Shock Factor 1 Function by Impairing the Recruitment of Positive Transcription Elongation Factor b to the hsp70 Promoter
Young Ju Yoon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis
Marissa V. Powers et al.
CANCER CELL (2008)
Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel
Ayana Sawai et al.
CANCER RESEARCH (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis
Chengkai Dai et al.
CELL (2007)
Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors
J-N Min et al.
ONCOGENE (2007)
The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease
Justin Lamb et al.
SCIENCE (2006)
Substrate transfer from the chaperone Hsp70 to Hsp90
H Wegele et al.
JOURNAL OF MOLECULAR BIOLOGY (2006)
Heat shock-independent induction of multidrug resistance by heat shock factor 1
T Tchenio et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Blocking tumor cell migration and invasion with biphenyl isoxazole derivative KRIBB3, a synthetic molecule that inhibits Hsp27 phosphorylation
KD Shin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Doxorubicin induces expression of multidrug resistance-associated protein 1 in human small cell lung cancer cell lines by the c-jun N-terminal kinase pathway
C Shinoda et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Dynamic remodeling of transcription complexes by molecular chaperones
RI Morimoto
CELL (2002)
Regulation of multidrug resistance 1 (MDR1)/P-glycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1)
NE Vilaboa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2
J Nylandsted et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Stepwise assembly of a glucocorticoid receptor•hsp90 heterocomplex resolves two sequential ATP-dependent events involving first hsp70 and then hsp90 in opening of the steroid binding pocket
Y Morishima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
